From Pilot to Production: Navigating AI Adoption Through Risk-First Prioritisation
Author: Diana Gamez, Head of Data & AI Engineering
Category: Innovation & Technology
Format: Whitepaper
Estimated read time: ~15 min
Basel, Switzerland – June 2, 2025
The adoption of artificial intelligence (AI) in the Life Sciences sector is accelerating, yet organisations continue to struggle with moving beyond proof-of-concept (POC) projects. Despite AI’s potential to reduce human error, improve efficiency, and lower costs, the sector’s high regulatory burden and low risk tolerance often stall initiatives before they reach production.
MIGx proposes a risk-first approach to AI prioritisation. Rather than beginning with a broad inventory of use cases, organisations should first identify business processes with an existing tolerance for imperfection, those insulated from patient-facing impact and regulatory scrutiny. This reflects a shift away from the traditional bottom-up model, where numerous use cases are generated and refined before risk considerations are fully assessed.
By inverting this logic and starting with risk-tolerant processes, organisations can better align AI adoption with regulatory realities from the outset. This enables a faster, more confident path to real-world deployment.
Key strategic takeaways include:
- Prioritising AI investments where failure is manageable
- Accelerating time-to-production by integrating compliance early
- Building internal confidence and momentum through low-risk wins
- Creating a scalable roadmap that aligns with regulatory frameworks
As a partner with deep expertise at the intersection of AI, enterprise IT, and regulated industries, MIGx helps pharmaceutical and biotech companies identify practical entry points for AI and navigate the sector’s cultural and operational constraints. Drawing on experience across enterprise-scale Life Sciences environments, we enable clients to shift from exploration to execution, safely, strategically, and at scale, while aligning AI initiatives with the organisation’s risk appetite and compliance landscape.
New Insight from MIGx: From Pilot to Production
Download the full Whitepaper PDF
Download WhitepaperFAQs
Why do AI projects fail in pharma before reaching production?
Many AI initiatives in pharma stall after proof-of-concept because regulatory and compliance considerations are introduced too late. While pilots may demonstrate technical feasibility, they often encounter friction during legal review, audit scrutiny, and risk assessment. Without aligning initiatives to regulatory tolerance and operational constraints from the outset, organisations struggle to move from experimentation to deployment.
How can pharma organisations scale AI beyond proof of concept?
Scaling AI in pharma requires shifting the focus from technical capability to deployability. Instead of starting with a broad list of potential use cases, organisations should first identify business processes that can tolerate some degree of imperfection and where validation and oversight mechanisms already exist. By prioritising AI initiatives within these controlled environments, companies create production-ready successes that can later expand into more sensitive domains.
How does regulatory risk affect AI prioritisation in life sciences?
Regulatory risk directly shapes which AI initiatives can realistically reach production. In highly regulated processes with low tolerance for error, such as clinical or patient-facing workflows, AI deployment requires extensive validation and documentation. A risk-first approach recognises these constraints early and prioritises AI initiatives in areas with manageable compliance exposure.
What is a risk-first approach to AI adoption in life sciences?
A risk-first approach to AI adoption begins by mapping business processes according to regulatory exposure, error tolerance, and governance controls before selecting use cases. Rather than asking “What can we build?”, organisations ask “Where can AI operate safely and defensibly?” This sequencing increases the probability that AI initiatives move successfully from pilot to sustained production.
